Wednesday, June 10, 2026
🇺🇸 FDA

Drug profile · INN

normal

normal is an FDA-listed pharmaceutical active ingredient.

NMPA: clinical trials
Patents linked 20
Pipeline programs 59
News articles 0
Drug details — normal
Class
—
Route
—
Patents
20
Programs
59
Data quality
0.70
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

normal is an FDA-listed pharmaceutical active ingredient.

Key facts

INN normal

Approval history

Authority Status Date
NMPA clinical trials —

Pipeline programs

Search pipeline
  1. 2.16/VI/22 Phase 3 · Cardiol Therapeutics · Patients with functionally single ventricle (FSV - functiona
  2. 20190531 Phase 3 · Amgen · Behçet’s disease is a chronic, relapsing, multisystem inflam
  3. 80202135FNAIT3003 Phase 3 · Janssen-Cilag International N.V · Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
  4. ADX-324-301 Phase 3 · Anaxis Pharma · Hereditary Angioedema
  5. APHP191047 Phase 3 · PARItec · Patients with microcirculatory abnormalities during septic s
  6. APHP200017 Phase 3 · PARItec · Adult patients with immune thrombocytopenia (ITP) with mild
  7. APHP241013 Phase 3 · PARItec · Young Adults and adults with R/R B-cell acute lymphoblastic
  8. ARGX-117-2302 Phase 3 · Argenx · Multifocal Motor Neuropathy

Related patents

Browse patents

  1. US 12428463

    Chimeric antigen receptors targeting abnormal glycobiology

    Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12234474

    Method to prevent the myelin abnormalites associated with arginase deficiency

    Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11793777

    Methods and compositions for treating conditions associated with an abnormal inflammatory response

    Expires Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11760786

    Chimeric antigen receptors targeting abnormal glycobiology

    Expires Mon Sep 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10912746

    Methods and compositions for treating conditions associated with an abnormal inflammatory response

    Expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10905666

    Methods and compositions for treating conditions associated with an abnormal inflammatory response

    Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10849867

    Methods and compositions for treating conditions associated with an abnormal inflammatory response

    Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10799468

    Methods and compositions for treating conditions associated with an abnormal inflammatory responses

    Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10774121

    Methods and compositions for treating neurodegenerative disorders and Alzheimer's Disease and improving normal memory

    Expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10772854

    Methods and compositions for treating conditions associated with an abnormal inflammatory response

    Expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10744103

    Methods and compositions for treating conditions associated with an abnormal inflammatory responses

    Expires Mon Aug 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10406158

    Methods and compositions for treating abnormal cell growth

    Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10292951

    Methods and compositions for treating conditions associated with an abnormal inflammatory responses

    Expires Mon May 16 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10221223

    Methods and compositions for treating neurodegenerative disorders and alzheimer's disease and improving normal memory

    Expires Mon Feb 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. CA 3043000

    DERIVES DE PROSTAGLANDINE LIBERANT DE L'OXYDE NITRIQUE POUR LE TRAITEMENT DU GLAUCOME A TENSION NORMALE

    Expires Wed May 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9962385

    Methods and compositions for treating abnormal cell growth

    Expires Mon May 03 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9512191

    Methods and compositions for treating neurodegenerative disorders and alzheimer's disease and improving normal memory

    Expires Mon Dec 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 8951794

    Methods and compositions for treating neurodegenerative disorders and Alzheimer's disease and improving normal memory

    Expires Mon Feb 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 8945858

    Methods and compositions for treating neurodegenerative disorders and alzheimer's disease and improving normal memory

    Expires Mon Jan 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 8841266

    Pharmaceutical composition and method for regulating abnormal cellular proliferation

    Expires Mon Sep 18 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is normal?

normal is an FDA-listed pharmaceutical active ingredient.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.